Salute e Benessere

Compass Pathways appoints Teri Loxam as Chief Financial Officer

Teri brings to Compass deep and extensive strategic experience working for publicly traded companies, in the pharmaceutical and biotechnology sectors, and beyond. She joins the company from Gameto, where she was CFO and played a pivotal role in negotiating multiple licensing agreements and helping to develop the regulatory and commercial strategy for their lead product. Teri previously served as CFO and Chief Operating Officer of Kira Pharmaceuticals, where she advanced their lead asset...
Nasdaq GlobeNewswire
07/12/2023

ARTBIO Raises Oversubscribed and Upsized $90 Million Series A Financing to…

Management team expanded with appointments of radiopharmaceutical experts, Philippe Dasse, Pharm.D., and Daniel Rossetto Management team expanded with appointments of radiopharmaceutical experts, Philippe Dasse, Pharm.D., andDaniel Rossetto CAMBRIDGE, Mass.,OSLO, Norway,LONDON, andBASEL, Switzerland,Dec. 7, 2023/PRNewswire/ -- ARTBIO, Inc. (ARTBIO), a clinical-stage radiopharmaceutical company developing a new class of targeted alpha radioligand therapies (ARTs),...
PR Newswire
07/12/2023

Under the patronage of Theyab bin Mohamed bin Zayed HE Reem Al Hashimy announced…

At the launch, 13 year old environmental activist Ghaya Al Ahbabi took an active role. Winner of the Environment Award for Children from the Supreme Court of Motherhood and Childhood, Ghaya led an engaging discussion with Mayor of Tirana At the launch, 13 year old environmental activistGhaya Al Ahbabitook an active role. Winner of the Environment Award for Children from the Supreme Court of Motherhood and Childhood, Ghaya led an engaging discussion with Mayor of Tirana On this occasion,...
PR Newswire
07/12/2023

Virbac : Declaration of the number of shares and voting rights 11/2023

DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of voting rights and of shares representing the share capital (Article 223-16 of the General regulations of the French Financial Market Authority – Autorité des Marchés Financiers)Quotation place: Euronext Paris Compartiment A ISIN code: FR0000031577DateTotal number of shares representing the share capitalTotal number of voting rightsNovember, 30 20238 458 000Gross total of voting...
Nasdaq GlobeNewswire
07/12/2023

Global Healthcare Data Storage Market to Surpass $11.16 Billion by 2030 -…

The global healthcare data storage market is driven by two key factors. Firstly, the increasing volume of healthcare data generated globally is propelling the demand for efficient storage solutions. The digitization of healthcare records, growing adoption of electronic health records (EHRs), and advancements in medical imaging technologies have resulted in a massive amount of data being generated in the healthcare sector. To effectively manage this data, healthcare organizations are increasingly…
PR Newswire
07/12/2023

Ipsen confirms U.S. FDA grants priority review for New Drug Application for…

New Drug Application granted priority review with PDUFA date set for June 10, 2024European Medicines Agency (EMA) has also validated the Marketing Authorization Application (MAA) for elafibranor Investigational elafibranor is the first novel second-line treatment for primary biliary cholangitis (PBC) to be filed in E.U. and U.S. in nearly a decadeParis (France), December 07, 2023–Ipsen (Euronext: IPN; ADR: IPSEY) and GENFIT (Nasdaq and Euronext: GNFT)today announced...
Nasdaq GlobeNewswire
07/12/2023

Vesper Bio doses first volunteer in Phase I study of first-in-class oral…

Paul Little, PhD, Chief Executive Officer of Vesper Bio, said: "We have taken a significant step forward in bringing VES001 closer to treating patients suffering from FTD(GRN). This is a devasting disease for both patients and their families and we hope to show that this is a potentially game-changing treatment. The role of progranulin is becoming better understood, with clinical validation using antibody approaches, and pre-clinical trials with our small molecule, VES001, have shown the…
PR Newswire
07/12/2023

Montgó Lifestyle moves to new location for further growth

"We are committed to providing exceptional care and strive to create an environment that is both soothing and inspiring for our participants," said Rogier Buningh, founder of Montgó Lifestyle. The move to the interior of Costa Blanca,Spain, offers expanded capacity with 15 rooms and suites. Montgó Lifestyle Care focuses on personal counselling for individuals who need help due to burnout, addiction, or depression. Erik Dijkshoorn, co-owner of Montgó Lifestyle, added: "Our…
PR Newswire
07/12/2023

Sectra leads the market in PACS considerations and selections

"It is important to recognize that even though Sectra has considerable opportunities with new healthcare providers, 98% of our existing surveyed customers said Sectra was part of their long-term plans. This reinforces our belief that excellent products and happy customers will drive future business," says Isaac Zaworski, President of Sectra Inc. "It is important to recognize that even though Sectra has considerable opportunities with new healthcare providers, 98% of our existing…
PR Newswire
07/12/2023

Systemair AB Interim Report Q2 2023/24

Roland Kasper, President and CEO, comments: Roland Kasper, President and CEO, comments: "Systemair's second quarter shows evidence of continued growth with sales increasing by 4.9 percent. Adjusted for divestment of the air conditioning business and acquisitions last year, growth totalled 5.1 percent in the quarter. Operating profit for the period improved by 12 percent toSEK 322 million(288)." For further information contact: Roland Kasper, CEO, + 46 73 094 40 13 ...
PR Newswire
07/12/2023

MC2 Therapeutics Announces Completion of Enrollment in MC2-25 Ph2 Chronic Kidney…

MC2 Therapeutics Announces Completion of Enrollment in MC2-25 Ph2 Chronic Kidney Disease-associated Pruritus Trial MC2-25 CKD is a first-in-class drug candidate and a potential breakthrough in the understanding and treatment of urea associated skin diseases that has puzzled scientists for decadesMC2-25 CKD uses a di-peptide as an iso-cyanate scavenger to inhibit carbamylation of amino acids and proteins in the skinMC2-25 CKD has the potential to become the world's first approved...
Nasdaq GlobeNewswire
07/12/2023

Press Release: Sarclisa® (isatuximab) Phase 3 trial met primary endpoint of…

Sarclisa ®(isatuximab) Phase 3 trial met primary endpoint of progression free survival in patients with newly diagnosed multiple myeloma not eligible for transplantSarclisa added to bortezomib, lenalidomide and dexamethasone (VRd) significantly reduced the risk of disease progression or death compared with VRd aloneFirst global Phase 3 study to report positive results with an anti-CD38 therapy in combination with VRd in transplant-ineligible patients, reinforcing the potential for...
Nasdaq GlobeNewswire
07/12/2023

Imlifidase demonstrated positive safety, tolerability, and early efficacy…

Dr. Achim Kaufhold, Chief Medical Officer, Hansa Biopharma said, "The results of 15-HMedIdeS-09 are very encouraging. Imlifidase was safe and well tolerated, and when compared to previously published data, a rapid improvement across several efficacy outcome measures was observed in patients treated with imlifidase in combination with standard of care. Immunoglobulin G (IgG) antibodies are thought to play an important role in GBS disease. With its ability to rapidly cleave IgGs, imlifidase…
PR Newswire
07/12/2023

Santhera Appoints Executive Committee Members as it Transitions into Commercial…

Pratteln, Switzerland, December 7, 2023 – Santhera Pharmaceuticals (SIX: SANN) announces the promotion of Geert Jan van Daal, MD, PhD, to Chief Commercial Officer (CCO) and of Marc Schrader to Chief Technology Officer (CTO). Both will join the six-member Executive Committee effective January 1, 2024. “Santhera is transitioning to the commercial phase and will make AGAMREE® (vamorolone) available to patients in Europe starting in Germany in early 2024, subject to approval by the European...
Nasdaq GlobeNewswire
07/12/2023

Ipsen confirms U.S. FDA grants priority review for New Drug Application for…

New Drug Application granted priority review with PDUFA date set for June 10, 2024European Medicines Agency (EMA) has also validated the Marketing Authorization Application (MAA) for elafibranor Investigational elafibranor is the first novel second-line treatment for primary biliary cholangitis (PBC) to be filed in E.U. and U.S. in nearly a decade PARIS, FRANCE, 07 December 2023 -Ipsen (Euronext: IPN; ADR: IPSEY) and GENFIT (Nasdaq and Euronext: GNFT) today announced that the...
Nasdaq GlobeNewswire
07/12/2023

Capital Markets Day 2023 - Ipsen outlines next phase of growth & transformation…

PARIS, FRANCE, 7 December 2023 -Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical company, today holds its Capital Markets Day in London, U.K. “Ipsen has made significant progress since our strategic roadmap was implemented three years ago and is today in a great spot,” commented David Loew, Chief Executive Officer, Ipsen. “Our business has been transformed, with the focus on Specialty Care now supported by a stronger pipeline and momentum from our growth...
Nasdaq GlobeNewswire
07/12/2023

Press Release: Sanofi Pipeline Transformation to Accelerate Growth Driven by…

R&D DaySanofi Pipeline Transformation to Accelerate Growth Driven by Record Number of Potential Blockbuster Launches, Paving the Way to Industry Leadership in ImmunologyDetails strong pipeline including Sanofi's record 12 blockbuster opportunities under clinical evaluation: 9 innovative medicines and vaccines with €2 to 5 billion peak sales potential, and 3 'pipeline-in-a-product' assets with a potential of over €5 billion peak sales Strategic transformation through R&D...
Nasdaq GlobeNewswire
07/12/2023

Innovent Biologics and Synaffix Expand ADC Collaboration Following Positive…

Under the terms of the expanded agreement, Innovent will be responsible for the research, development, manufacturing and commercialization of new ADC candidates. Synaffix is eligible to receive an upfront payment plus potential milestone payments and royalties on commercial sales for each licensed target. Under the terms of the expanded agreement, Innovent will be responsible for the research, development, manufacturing and commercialization of new ADC candidates. Synaffix is eligible to...
PR Newswire
07/12/2023

IonOpticks and Newomics broaden chromatography accessibility for Agilent mass…

Thanks to Newomics' innovative development of the UniESI source, IonOpticks' Aurora Series columns are now seamlessly compatible with Agilent mass spectrometers. This latest enhancement opens new avenues for researchers and laboratories using Agilent mass specs to leverage the superior performance of the Aurora Series column range, and to explore the benefits and possibilities of nano and micro flow methods Thanks to Newomics' innovative development of the UniESI source, IonOpticks' Aurora...
PR Newswire
07/12/2023

LT Foods brand 'DAAWAT®' Basmati recognised as the 'Top Brand' in Canstar Blue's…

DAAWAT® scored 5 stars in the rating encompassing parameters like taste, texture, packaging convenience, variety and range and overall satisfaction. The sample comprised Australians who had bought dry rice from a supermarket or grocer in the last 3 months. The respondents rated their satisfaction on a scale of zero to ten, with zero accounting for 'extremely dissatisfied' and ten for 'extremely satisfied'. DAAWAT ® scored 5 stars in the rating encompassing parameters like taste, texture,...
PR Newswire
07/12/2023

Positive Topline Results from Phase II OPALESCENCE Study of TLX250-CDx in Triple…

The OPALESCENCE study (ClinicalTrials.gov ID NCT04758780) was undertaken by Dr. Caroline Rousseau at the Institut de Cancérologie de l'Ouest (ICO) in St Herblain (France). The primary objective was to evaluate how CAIX-targeted imaging with PET can be utilised for the diagnosis and staging of TNBC and to develop a deeper understanding of CAIX as a potential therapeutic target in this patient population where there is significant unmet medical need. The OPALESCENCE study (ClinicalTrials...
PR Newswire
06/12/2023

Metastatic Castration-Sensitive Prostate Cancer Market to Skyrocket at…

Key Takeaways from the Metastatic Castration-Sensitive Prostate Cancer Market Report Key Takeaways from the Metastatic Castration-Sensitive Prostate Cancer Market Report Discover which therapies are expected to grab the major mCSPC market share @ Metastatic Castration-Sensitive Prostate Cancer Market Report Metastatic Castration-Sensitive Prostate Cancer Epidemiology 65-74 years age group, accounted for the highest number of mCSPC cases in 2022 in the US, as per DelveInsight analysi...
PR Newswire
06/12/2023

Monthly information related to total number of voting rights and shares…

Monthly information related to total number of voting rights and shares composing the share capital _ November 30, 2023 Article 223-16 of general regulation of French Autorité des Marchés FinanciersListing markets:Euronext Paris from Euronext (Market segment C - ISIN Code: FR001400K4B1- Symbol: PHXM) &Nasdaq Global Select Market in the United-States (Symbol: PHXM) Website : www.phaxiam.com DateTotal of shares composing the share capitalTotal of brut(1)...
Nasdaq GlobeNewswire
06/12/2023

Study results of psilocybin treatment in bipolar II depression published in JAMA…

Believed to be first ever psilocybin clinical trial for treatment of bipolar II depression JAMA Psychiatry that demonstrates the potential for investigational COMP360 psilocybin treatment in treatment-resistant bipolar type II disorder (bipolar II). Results from the investigator-initiated open-label study were first presented at the Annual Meeting of the American College of Neuropsychopharmacology in 2022.The study, which was conducted by Dr Scott Aaronson at Sheppard Pratt, Baltimore,...
Nasdaq GlobeNewswire
06/12/2023
Altri  Comunicati